Emerging Biosimilars in Therapeutics

A biosimilar medicine is developed to be highly similar to a biological medicine that is already approved and available for patients, once the original patent has expired.

It is predicted that as patents expire over the next five years for a number of biological medicines with high sales, the development of biosimilar medicines for the treatment of cancer, diabetes, rheumatoid arthritis and multiple sclerosis will be seen. It is also predicted that the monoclonal antibodies (mABs) will comprise a large proportion of the biosimilars market along with biosimilar insulins, which are also expected to enter the insulin landscape in the coming years as the patents for major insulin products begin to expire. The proportion of different biosimilars that reached market are Low Molecular Weight Heparins 44%, Epoetins 19%, HGH 11%, G-CSFs 7%, Interferons 6%, Insulins 5%, Others 8%.

  • Biosimilars in Cancer therapeutics
  • Biosimilar Interleukins
  • Biosimilar Epoetins
  • Biosimilar TNF-α
  • Biosimilars in Fertility Treatment
  • Recombinant blood products
  • Biosimilar monoclonal antibodies
  • Recombinant therapeutic proteins
  • Biosimilar peptides
  • Insulin Biosimilars
  • Growth hormones
  • Recombinant vaccines
  • Biosimilars in rheumatology
  • Biosimilars interferon

Emerging Biosimilars in Therapeutics Conference Speakers

Recommended Sessions

Related Journals

Are you interested in